{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:37:28Z","timestamp":1770971848822,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T00:00:00Z","timestamp":1250812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11739-009-0293-9","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T12:52:38Z","timestamp":1250772758000},"page":"471-477","source":"Crossref","is-referenced-by-count":10,"title":["Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review"],"prefix":"10.1007","volume":"4","author":[{"given":"Davide","family":"Imberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Dall\u2019Asta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Giorgi","family":"Pierfranceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,21]]},"reference":[{"key":"293_CR1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","volume":"158","author":"MD Silverstein","year":"1998","unstructured":"Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585\u2013593","journal-title":"Arch Intern Med"},{"key":"293_CR2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-2006-951293","volume":"32","author":"W Ageno","year":"2006","unstructured":"Ageno W, Squizzato A, Garcia D, Imberti D (2006) Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 32:651\u2013658","journal-title":"Semin Thromb Hemost"},{"key":"293_CR3","first-page":"756","volume":"98","author":"AT Cohen","year":"2007","unstructured":"Cohen AT, Agnelli G, Anderson FA et al (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Conflict of interest statementThromb Haemost 98:756\u2013764","journal-title":"Conflict of interest statementThromb Haemost"},{"key":"293_CR4","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","volume":"126","author":"WH Geerts","year":"2004","unstructured":"Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338S\u2013400S","journal-title":"Chest"},{"key":"293_CR5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.blo.0000194726.55372.4d","volume":"441","author":"VD Pellegrini","year":"2005","unstructured":"Pellegrini VD, Donaldson CT, Farber DC et al (2005) Prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop 441:56\u201362","journal-title":"Clin Orthop"},{"key":"293_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.blo.0000229357.19867.84","volume":"452","author":"VD Pellegrini","year":"2006","unstructured":"Pellegrini VD, Donaldson CT, Farber DC et al (2006) The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop 452:21\u201327","journal-title":"Clin Orthop"},{"key":"293_CR7","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"WH Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GM et al (2008) Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 133:381S\u2013453S","journal-title":"Chest"},{"key":"293_CR8","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.08-0673","volume":"133","author":"JI Weitz","year":"2008","unstructured":"Weitz JI, Hirsh J, Samama MM (2008) New antithrombotic drug. American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 133:234S\u2013256S","journal-title":"Chest"},{"key":"293_CR9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1378\/chest.126.2.501","volume":"126","author":"AG Turpie","year":"2004","unstructured":"Turpie AG, Bauer KA, Eriksson BI et al (2004) Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 126:501\u2013508","journal-title":"Chest"},{"key":"293_CR10","doi-asserted-by":"crossref","first-page":"330S","DOI":"10.1378\/chest.08-0677","volume":"133","author":"TE Warkentin","year":"2008","unstructured":"Warkentin TE, Greinacher A, Koster A et al (2008) Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 133:330S\u2013380S","journal-title":"Chest"},{"key":"293_CR11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.V75.9.1753.1753","volume":"75","author":"B Furie","year":"1990","unstructured":"Furie B, Furie BC (1990) Molecular basis of vitamin K-dependent \u03b3-carboxylation. Blood 75:1753\u20131762","journal-title":"Blood"},{"key":"293_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/14750708.5.2.177","volume":"5","author":"J Harenberg","year":"2008","unstructured":"Harenberg J (2008) Indirect and direct anticoagulants predominantly inhibiting factor Xa. Therapy 5:177\u2013192","journal-title":"Therapy"},{"key":"293_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-006-5579-4","volume":"21","author":"KA Bauer","year":"2006","unstructured":"Bauer KA (2006) New anticoagulants: anti IIa vs anti Xa\u2014is one better? J Thromb Thrombolysis 21:67\u201372","journal-title":"J Thromb Thrombolysis"},{"key":"293_CR14","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","volume":"27","author":"AG Turpie","year":"2007","unstructured":"Turpie AG (2007) Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238\u20131247","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"293_CR15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"J Strassburger","year":"2005","unstructured":"Strassburger J, Wilmen A, Pohlmann J et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2014an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514\u2013521","journal-title":"J Thromb Haemost"},{"key":"293_CR16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","volume":"61","author":"D Kubitza","year":"2005","unstructured":"Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59\u20137939\u2014an oral, direct factor Xa inhibitor\u2014after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873\u2013880","journal-title":"Eur J Clin Pharmacol"},{"key":"293_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/ATVBAHA.108.162677","volume":"28","author":"PL Gross","year":"2008","unstructured":"Gross PL, Weitz JI (2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28:380\u2013386","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"293_CR18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M et al (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59\u20137939) in healthy subjects. J Clin Pharmacol 47:218\u2013226","journal-title":"J Clin Pharmacol"},{"key":"293_CR19","doi-asserted-by":"crossref","unstructured":"Kubitza D, Becka M, Mueck W et al (2006) The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban an oral, direct factor Xa inhibitor. Blood 108 (Abstract 905)","DOI":"10.1182\/blood.V108.11.905.905"},{"key":"293_CR20","doi-asserted-by":"crossref","unstructured":"Halabi A, Maatouk H, Klause N et al (2006) Effects of renal impairment on the pharmacology of rivaroxaban (BAY 59-7939) an oral, direct, factor Xa inhibitor. Blood 108 (Abstract 913)","DOI":"10.1182\/blood.V108.11.913.913"},{"key":"293_CR21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","volume":"46","author":"D Kubitza","year":"2006","unstructured":"Kubitza D, Becka M, Zuehlsdorf M et al (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59\u20137939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549\u2013558","journal-title":"J Clin Pharmacol"},{"key":"293_CR22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","volume":"46","author":"D Kubitza","year":"2006","unstructured":"Kubitza D, Becka M, Mueck W et al (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014are not affected by aspirin. J Clin Pharmacol 46:981\u2013990","journal-title":"J Clin Pharmacol"},{"key":"293_CR23","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","volume":"3","author":"A Turpie","year":"2005","unstructured":"Turpie A, Fisher W, Bauer K et al (2005) BAY 59\u20137939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 3:2479\u20132486","journal-title":"J Thromb Haemost"},{"key":"293_CR24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","volume":"4","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris LC, Dahl OE et al (2006) Oral, direct factor Xa inhibition with BAY 59\u20137939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121\u2013128","journal-title":"J Thromb Haemost"},{"key":"293_CR25","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","volume":"114","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris LC, Dahl OE et al (2006) A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59\u20137939), for thromboprophylaxis after total hip replacement. Circulation 114:2374\u20132381","journal-title":"Circulation"},{"key":"293_CR26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","volume":"120","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Borris LC, Dahl OE et al (2007) Dose-escalation study of rivaroxaban (BAY 59\u20137939)\u2014an oral, direct factor Xa inhibitor\u2014for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685\u2013693","journal-title":"Thromb Res"},{"key":"293_CR27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","volume":"100","author":"W Mueck","year":"2008","unstructured":"Mueck W, Borris LC, Dahl OE et al (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453\u2013461","journal-title":"Thromb Haemost"},{"key":"293_CR28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765\u20132775","journal-title":"N Engl J Med"},{"key":"293_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Eriksson BI et al (2008) Extended duration of rivaroxaban versus short term enoxaparin for the prevention on venous thromboembolism after total hip arthroplasty: a double blind, randomized controlled trial. Lancet 372:29\u201337","journal-title":"Lancet"},{"key":"293_CR30","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776\u20132786","journal-title":"N Engl J Med"},{"key":"293_CR31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","volume":"373","author":"A Turpie","year":"2009","unstructured":"Turpie A, Lassen M, Davidson B et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673\u20131680","journal-title":"Lancet"},{"key":"293_CR32","doi-asserted-by":"crossref","unstructured":"Turpie A, Lassen M, Kakkar AJ et al (2008) A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism, death and bleeding. American Society of Haematology 2008 annual meeting, December 6\u20139, 2008, San Francisco, Abstract 36","DOI":"10.1182\/blood.V112.11.36.36"},{"key":"293_CR33","first-page":"2","volume":"1","author":"D Imberti","year":"2008","unstructured":"Imberti D, Dall\u2019Asta C (2008) Clinical benefits of rivaroxaban for thromboprophylaxis after major orthopaedic surgery. Adv Orthop 1:2\u20138","journal-title":"Adv Orthop"},{"key":"293_CR34","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJ Pinto","year":"2007","unstructured":"Pinto DJ, Orwat MJ, Koch S et al (2007) Discovery of 1-(4-methoxyphenyl)7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339\u20135556","journal-title":"J Med Chem"},{"key":"293_CR35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","volume":"6","author":"PC Wong","year":"2007","unstructured":"Wong PC, Crain EJ, Xin B et al (2007) Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820\u2013829","journal-title":"J Thromb Haemost"},{"key":"293_CR36","doi-asserted-by":"crossref","unstructured":"Raghavan N, Frost CE, Yu Z et al (2008) Apixaban metabolism and pharmacokinetics following oral administration to humans. Drug Metab Dispos [Epub ahead of print]","DOI":"10.1124\/dmd.108.023143"},{"key":"293_CR37","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"MR Lassen","year":"2007","unstructured":"Lassen MR, Davidson BL, Gallus A et al (2007) The efficacy of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368\u20132375","journal-title":"J Thromb Haemost"},{"key":"293_CR38","unstructured":"Lassen M, Gallus A, Pineo G et al (2008) Randomized double-blind comparison of apixaban with enoxaparin for thromboprophyaxis after knee replacement: the ADVANCE-1 trial. American Society of Haematology 2008 annual meeting, December 6\u20139, 2008, San Francisco, Abstract 31"},{"key":"293_CR39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","volume":"5","author":"G Agnelli","year":"2007","unstructured":"Agnelli G, Haas SK, Krueger KA (2007) A phase II study of the oral factor Xa inhibitor LY517717 for prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 5:746\u2013753","journal-title":"J Thromb Haemost"},{"key":"293_CR40","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Turpie AGG, Lassen MR et al (2007) A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement. J Thromb Haemost 5:1660\u20131665","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"293_CR41","first-page":"A39","volume":"36","author":"A Gruber","year":"2007","unstructured":"Gruber A, Marzec UM, Buetehorn U et al (2007) Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons. Pathophysiol Haemost Thromb 36(Suppl 1):A39 (abstract)","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"Suppl 1","key":"293_CR42","first-page":"A40","volume":"36","author":"E Perzborn","year":"2007","unstructured":"Perzborn E, Tinel H (2007) FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 36(Suppl 1):A40 (abstract)","journal-title":"Pathophysiol Haemost Thromb"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0293-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-009-0293-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0293-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:47:35Z","timestamp":1685101655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-009-0293-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,21]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s11739-009-0293-9","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,21]]}}}